-
Something wrong with this record ?
Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma
Petra Schneiderova, Tomas Pika, Petr Gajdos, Regina Fillerova, Pavel Kromer, Milos Kudelka, Jiri Minarik, Tomas Papajik, Vlastimil Scudla and Eva Kriegova
Language English Country United States
Grant support
NT12451
MZ0
CEP Register
NT14400
MZ0
CEP Register
NV16-32339A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Free Medical Journals
from 2010
Freely Accessible Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
- MeSH
- Adrenomedullin MeSH
- Transplantation, Autologous MeSH
- Cytokines MeSH
- B-Cell Activating Factor MeSH
- Immunoassay MeSH
- Blood Proteins analysis MeSH
- Intercellular Signaling Peptides and Proteins MeSH
- Multiple Myeloma MeSH
- Monoclonal Gammopathy of Undetermined Significance MeSH
- Biomarkers, Tumor MeSH
- Growth Differentiation Factor 15 MeSH
- Stem Cell Transplantation MeSH
Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenomedullin (ADM, Pcorr= .0004), Growth differentiation factor 15 (GDF15, Pcorr= .003), and soluble Major histocompatibility complex class I-related chain A (sMICA, Pcorr= .023), all prosurvival and chemoprotective factors for myeloma cells, were detected in MM comparing to MGUS. Comparison of MGUS and healthy subjects revealed elevation of angiogenic and antia-poptotic midkine (Pcorr= .0007) and downregulation of Transforming growth factor beta 1 (TGFB1, Pcorr= .005) in MGUS. Importantly, altered serum pattern was associated with MM-ASCT compared to paired MM at the diagnosis as well as to healthy controls, namely by upregulated B-Cell Activating Factor (sBAFF) (Pcorr< .006) and sustained elevation of other pro-tumorigenic factors. In conclusion, the serum fingerprints of MM and MM-ASCT were characteristic by elevated levels of prosurvival and chemoprotective factors for myeloma cells.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19039231
- 003
- CZ-PrNML
- 005
- 20191112152501.0
- 007
- ta
- 008
- 191106s2016 xxu f 000 0|eng||
- 009
- AR
- 024 0_
- $a 10.18632/oncotarget.11242 $2 doi
- 035 __
- $a (Pubmed)29050213
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Schneiderová, Petra $7 xx0199226 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 245 10
- $a Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma / $c Petra Schneiderova, Tomas Pika, Petr Gajdos, Regina Fillerova, Pavel Kromer, Milos Kudelka, Jiri Minarik, Tomas Papajik, Vlastimil Scudla and Eva Kriegova
- 520 9_
- $a Serum protein fingerprints associated with MGUS and MM and their changes in MM after autologous stem cell transplantation (MM-ASCT, day 100) remain unexplored. Using highly-sensitive Proximity Extension ImmunoAssay on 92 cancer biomarkers (Proseek Multiplex, Olink), enhanced serum levels of Adrenomedullin (ADM, Pcorr= .0004), Growth differentiation factor 15 (GDF15, Pcorr= .003), and soluble Major histocompatibility complex class I-related chain A (sMICA, Pcorr= .023), all prosurvival and chemoprotective factors for myeloma cells, were detected in MM comparing to MGUS. Comparison of MGUS and healthy subjects revealed elevation of angiogenic and antia-poptotic midkine (Pcorr= .0007) and downregulation of Transforming growth factor beta 1 (TGFB1, Pcorr= .005) in MGUS. Importantly, altered serum pattern was associated with MM-ASCT compared to paired MM at the diagnosis as well as to healthy controls, namely by upregulated B-Cell Activating Factor (sBAFF) (Pcorr< .006) and sustained elevation of other pro-tumorigenic factors. In conclusion, the serum fingerprints of MM and MM-ASCT were characteristic by elevated levels of prosurvival and chemoprotective factors for myeloma cells.
- 650 _2
- $a cytokiny $7 D016207
- 650 _2
- $a mezibuněčné signální peptidy a proteiny $7 D036341
- 650 _2
- $a krevní proteiny $x analýza $7 D001798
- 650 _2
- $a imunoanalýza $7 D007118
- 650 _2
- $a růstový diferenciační faktor 15 $7 D055436
- 650 _2
- $a monoklonální gamapatie nejasného významu $7 D008998
- 650 _2
- $a mnohočetný myelom $7 D009101
- 650 _2
- $a autologní transplantace $7 D014182
- 650 _2
- $a transplantace kmenových buněk $7 D033581
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a adrenomedulin $7 D053607
- 650 _2
- $a faktor aktivující B-buňky $7 D053264
- 700 1_
- $a Pika, Tomáš $7 xx0071238 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Gajdoš, Petr $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Fillerová, Regina $7 xx0147662 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Kromer, Pavel $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Kudelka, Miloš $u Department of Computer Science, Faculty of Electrical Engineering and Computer Science, VSB-Technical University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Minařík, Jiří $7 xx0106330 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Papajík, Tomáš, $d 1967- $7 xx0060566 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Ščudla, Vlastimil, $d 1946- $7 jn20000402953 $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
- 700 1_
- $a Kriegová, Eva, $d 1968- $7 xx0142572 $u Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 773 0_
- $t Oncotarget $x 1949-2553 $g Roč. 8, č. 41 (2016), s. 69408-69421 $w MED00184852
- 910 __
- $a ABA008 $b sig $y 4 $z 0
- 990 __
- $a 20191106140747 $b ABA008
- 991 __
- $a 20191112152738 $b ABA008
- 999 __
- $a ok $b bmc $g 1462154 $s 1077819
- BAS __
- $a 3
- BMC __
- $a 2016 $b 8 $c 41 $d 69408-69421 $x MED00184852 $i 1949-2553 $m Oncotarget
- GRA __
- $a NT12451 $p MZ0
- GRA __
- $a NT14400 $p MZ0
- GRA __
- $a NV16-32339A $p MZ0
- LZP __
- $a NLK 2019/lp